drugset / Trial / NCT00575861

Zileuton and Exhaled Nitric Oxide in Asthmatics

NCT00575861

Phase 4 Completed 19 enrolled Gelb, Arthur F., M.D.
Non-randomizedCrossoverSingle-blindTreatment

Summary

Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven pathways of inflammation. The addition of zileuton which is a leukotriene synthesis inhibitor by itself or together with inhaled corticosteroids should reduce nitric oxide gas exchange.

Timeline

Start
2005-09
Primary completion
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Zileuton Small molecule 600 mg Oral

Indications